Evidence map›Paper›PMID 38310398›Full record

ReviewCurrent medicinal chemistry2025

MNK: A Novel Promising Target for Cancer Immunotherapy.

Pei Shu, Yanna Lei, Ge Gao, Xiaoyu Li, Diyuan Qin, Benxia Zhang, Yue Chen, Qizhi Ma, Yongsheng Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Pei ShuDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Yanna LeiDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, 610041, China.
Ge GaoClinical Trial Center, National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Xiaoyu LiDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Diyuan QinDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Benxia ZhangDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Yue ChenDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Qizhi MaDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan, 610041, China.
Yongsheng WangDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Sichuan University · CNSichuan Cancer Hospital · CNNational Medical Products Administration · CN

Funding

National Natural Science Foundation of China 82073369, 8227102577
6 · The paper itself

Abstract

Cancer immunotherapy has demonstrated remarkable success in the treatment of multiple advanced malignancies, especially approaches to target the immune checkpoint. Nonetheless, the limited response rate remains a barrier to broader application. Identifying other ways to extend the beneficiaries to a large extent is needed. Emerging evidence has shown that mitogen-activated protein kinase-interacting kinases (MNKs) could be regarded as a novel, attractive target for cancer immunotherapy that is closely correlated with cancer biology and therapies. A comprehensive understanding of the role and mechanism of MNKs in cancer will shed light on the discovery of novel therapeutic strategies for cancer treatment. In this review, we outlined the structure of MNKs, their function and expression, and how MNKs affect tumor progression and elucidated the evidence supporting MNKs as a new promising treatment modality in human cancers.

Indexed as

ImmunotherapyIntracellular Signaling Peptides and ProteinsNeoplasmsProtein Serine-Threonine KinasesAnimalsHumansIntracellular Signaling Peptides and ProteinsProtein Serine-Threonine Kinasescancer therapyimmunotherapy.MAPKMNKnovel targetpromising target

Identifiers

PMID38310398
OpenAlexW4391522223

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.